Over the last decade, advances in genetics, neuroimaging and EEG have enabled the
aetiology of epilepsy to be identified earlier in the disease course than ever before. At the …

Epilepsy, a neurological disease characterized by recurrent seizures, is highly
heterogeneous in nature. Based on the prevalence, epilepsy is classified into two types …

Phenytoin is a long-standing, anti-seizure drug widely used in clinical practice. It has also
been evaluated in the context of many other illnesses in addition to its original epilepsy …

Next-generation sequencing technologies allow for rapid and inexpensive large-scale
genomic analysis, creating unprecedented opportunities to integrate genomic data into the …

The outbreak of Coronavirus disease 2019 (COVID-19) has evolved into an emergent global
pandemic. Many drugs without established efficacy are being used to treat COVID-19 …

Adverse drug reactions (ADRs) remain associated with significant mortality. Delayed
hypersensitivity reactions (DHRs) that occur greater than 6 h following drug administration …

Evaluating genes involved in the pharmacodynamics and pharmacokinetics of epilepsy
drugs is critical to better understand pharmacoresistant epilepsy. We reviewed the …

Background: Sex and gender-based differences are observed well beyond the sex organs
and affect several physiological and biochemical processes involved in the metabolism of …

Introduction Phenytoin is a frequently used drug treatment for epilepsy. Genetic
polymorphisms in the metabolism of phenytoin, particularly CYP2C9, are strongly …

Background and Objectives Being on a newer, second-, and third-generation antiseizure
medication (ASM) may represent an important marker of quality of care for people with …